{
    "clinical_study": {
        "@rank": "73891", 
        "acronym": "2MD-7H-2B", 
        "arm_group": [
            {
                "arm_group_label": "DP001", 
                "arm_group_type": "Experimental", 
                "description": "DP001 softgel capsules, 440 ng taken orally three times weekly after dialysis for 12 weeks"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo softgel capsules, taken orally three times weekly after dialysis for 12 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The goal of this study is to test a new vitamin D compound for its ability to reduce\n      parathyroid hormone levels in patients who are on hemodialysis."
        }, 
        "brief_title": "A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Actual"
        }, 
        "condition": [
            "Hyperparathyroidism, Secondary", 
            "Kidney Failure, Chronic"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hyperparathyroidism", 
                "Hyperparathyroidism, Secondary", 
                "Kidney Failure, Chronic", 
                "Renal Insufficiency"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a randomized, double-blind, placebo-controlled study of the vitamin D analog\n      2-methylene-19-nor-20S-1\u03b1,25-dihydroxyvitamin D3 (DP001) in patients with end-stage renal\n      disease (ESRD).  The effect of 12 weeks of oral administration of DP001 on serum parathyroid\n      hormone (PTH) levels will be evaluated in ESRD patients who have secondary\n      hyperparathyroidism."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men and non-pregnant women \u226518 years of age\n\n          -  Patient is diagnosed with ESRD and must be on hemodialysis 3 times per week for at\n             least 3 months prior to Screening Phase\n\n          -  Patient is currently being treated with pharmaceutical vitamin D for the treatment of\n             secondary hyperparathyroidism\n\n          -  Serum iPTH value \u2264500 pg/mL at first screening visit\n\n          -  Total serum calcium (corrected for albumin) \u226410.5 mg/dL at first screening visit\n\n          -  Serum phosphorus \u22647.0 mg/dL at first screening visit\n\n        Exclusion Criteria:\n\n          -  Currently taking any of the following: drugs affecting vitamin D metabolism,\n             digitalis, glucocorticoids, cyclosporine or other immunosuppressants, aluminum-based\n             phosphate binders\n\n          -  A daily intake >4000 IU vitamin D (D3 + D2)\n\n          -  Any investigational drug use within 10 half-lives of the drug (or within the previous\n             30 days if the half-life of the drug is unknown)\n\n          -  History of any of the following: ventricular dysrhythmias, severe congestive heart\n             failure, angina pectoris, myocardial infarction, coronary angioplasty, coronary\n             artery bypass grafting, multiple myeloma, calciphylaxis, active malignancy, end-stage\n             liver disease, active infections, clinically significant renal/urinary tract stones,\n             sarcoidosis, tuberculosis, parathyroidectomy\n\n          -  Major surgery within the past 3 months"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "62", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01922843", 
            "org_study_id": "2MD-7H-2B"
        }, 
        "intervention": {
            "arm_group_label": "DP001", 
            "intervention_name": "DP001 softgel capsules", 
            "intervention_type": "Drug", 
            "other_name": [
                "2-methylene-19-nor-20S-1\u03b1,25-(OH)2D3", 
                "PF-00217763", 
                "2MD"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Vitamin D", 
                "Vitamins"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Hemodialysis", 
        "lastchanged_date": "June 4, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Phoenix", 
                        "country": "United States", 
                        "state": "Arizona"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tucson", 
                        "country": "United States", 
                        "state": "Arizona"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Evanston", 
                        "country": "United States", 
                        "state": "Illinois"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Las Vegas", 
                        "country": "United States", 
                        "state": "Nevada"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Great Neck", 
                        "country": "United States", 
                        "state": "New York"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ridgewood", 
                        "country": "United States", 
                        "state": "New York"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charlotte", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fort Worth", 
                        "country": "United States", 
                        "state": "Texas"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Grand Prairie", 
                        "country": "United States", 
                        "state": "Texas"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 2B, Double-blind, Randomized, Placebo-controlled, Proof-of-concept Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis", 
        "overall_official": {
            "affiliation": "Massachusetts General Hospital", 
            "last_name": "Ravi Thadhani, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "The proportion of patients who achieve two consecutive > or = 30% decreases from his/her baseline serum iPTH level", 
            "safety_issue": "No", 
            "time_frame": "12 weeks, with weekly iPTH measurements"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01922843"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Mean percentage change in serum iPTH", 
            "safety_issue": "No", 
            "time_frame": "Baseline to 12 weeks"
        }, 
        "source": "Deltanoid Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Deltanoid Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}